Teva Pharmaceuticals
TEVA
737 hedge funds and large institutions have $21.8B invested in Teva Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 119 funds opening new positions, 239 increasing their positions, 303 reducing their positions, and 164 closing their positions.
3.23% more ownership
Funds ownership: 56.04% → 59.27% (+3.2%)
7% less funds holding
Funds holding: 795 → 737 (-58)
16% less capital invested
Capital invested by funds: $26B → $21.8B (-$4.23B)
21% less repeat investments, than reductions
Existing positions increased: 239 | Existing positions reduced: 303
23% less funds holding in top 10
Funds holding in top 10: 35 → 27 (-8)
27% less first-time investments, than exits
New positions opened: 119 | Existing positions closed: 164
33% less call options, than puts
Call options by funds: $433M | Put options by funds: $645M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$939M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$502M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$390M |
| 4 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$347M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$289M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$906M |
| 2 |
PC
PointState Capital
New York
|
-$416M |
| 3 |
Lazard Asset Management
New York
|
-$285M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$265M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$186M |
TEVA Hedge Fund Activity: Q4 2016 in Review
737 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2016, worth a combined $21.8B — down 16% from $26B a quarter earlier.
Sellers outnumbered buyers: 164 funds closed out of TEVA and 119 opened new positions — a net loss of 45 holders — while 303 trimmed existing stakes and 239 added.
The largest buyer was Capital Research Global Investors, adding an estimated $939M. The largest seller was Viking Global Investors, exiting entirely with an estimated $906M sold.
- 737 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2016, down from 795 in Q3 2016.
- Funds reported $21.8B of Teva Pharmaceuticals stock for Q4 2016, down 16% quarter-over-quarter.
- 119 funds opened new Teva Pharmaceuticals positions in Q4 2016 and 164 closed out, a net change of -45 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2016 was Capital Research Global Investors, an estimated $939M added.
- The largest Teva Pharmaceuticals seller in Q4 2016 was Viking Global Investors, an estimated $906M sold.
Based on aggregated 13F filings for Q4 2016.